Xanomeline, a cholinergic agonist, was initially evaluated for the treatment of Alzheimer’s disease and schizophrenia. Reference standards of Xanomeline API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
No Data Found
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
